About Neurocrine
Neurocrine is a company based in San Diego (United States) founded in 1992 was acquired by Immedica in January 2026. Neurocrine has raised $10 million across 4 funding rounds from investors including BB Biotech, Immedica and MQS Management. The company has 1,800 employees as of December 31, 2024. Neurocrine has completed 2 acquisitions, including Neurocrine UK and Soleno Life. Neurocrine offers products and services including Medicines and Clinical Studies. Neurocrine operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, PTC Therapeutics, Biohaven Pharmaceutical and Crinetics, among others.
- Headquarter San Diego, United States
- Employees 1800 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neurocrine Biosciences, Inc.
-
Annual Revenue
$2.36 B (USD)24.81as on Dec 31, 2024
-
Net Profit
$341.3 M (USD)36.68as on Dec 31, 2024
-
EBITDA
$624.1 M (USD)49.99as on Dec 31, 2024
-
Total Equity Funding
$10 M (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
BB Biotech
& 3 more
-
Employee Count
1800
as on Dec 31, 2024
-
Investments & Acquisitions
Neurocrine UK
& 1 more
-
Acquired by
Immedica
(Jan 08, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Neurocrine
Neurocrine is a publicly listed company on the NASDAQ with ticker symbol NBIX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Neurocrine
Neurocrine offers a comprehensive portfolio of products and services, including Medicines and Clinical Studies.
Treatments for neurological and neuropsychiatric disorders
Investigations into potential treatments for rare diseases
People of Neurocrine
Unlock access to complete
Leadership Team
82 people
Software Development Team
37 people
Neuropsych Team
34 people
Senior Team
34 people
Neurology Team
33 people
Regional Team
32 people
Product Management Team
31 people
Operations Team
27 people
Unlock access to complete
Funding Insights of Neurocrine
Neurocrine has successfully raised a total of $10M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neurocrine
Neurocrine has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include BB Biotech, Immedica and MQS Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Offers fundamentally driven quantitative global macro investment strategies as a registered adviser.
|
Locked | Locked | Locked |
Investor details for Neurocrine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neurocrine
Neurocrine has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Neurocrine UK and Soleno Life.
Investment portfolio details for Neurocrine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Hormone therapeutics for rare and chronic endocrine diseases are developed.
|
Locked | Locked | 2004 | Locked | |
|
Small molecule therapeutics for Prader-Willi Syndrome hyperphagia are developed.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Neurocrine
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Neurocrine
Detailed financials for Neurocrine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurocrine Comparisons
Peer comparison for Neurocrine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neurocrine
Neurocrine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, PTC Therapeutics, Biohaven Pharmaceutical and Crinetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
Detailed competitors of Neurocrine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurocrine
Complete news archive for Neurocrine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurocrine
Neurocrine was founded in 1992 and raised its 1st funding round 17 years after it was founded.
Neurocrine is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kevin Gorman is the current CEO of Neurocrine.
Neurocrine is a funded company, having raised a total of $10M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Neurocrine is 1,800.
Annual revenue of Neurocrine is $2.36B as on Dec 31, 2024.
Developer of small molecule therapeutics for endocrine and CNS disorders. The companys product line include elagolix, a gonadotropin-releasing hormone antagonist for endometriosis and uterine leiomyoma, and NBI-98854 a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.
Neurocrine's top competitors include Jazz Pharmaceuticals, Crinetics and PTC Therapeutics.
Neurocrine offers Medicines and Clinical Studies.
Yes, Neurocrine is publicly traded on NASDAQ under the ticker symbol NBIX.
Neurocrine has made 2 acquisitions, including Neurocrine UK, and Soleno Life.
Neurocrine has 4 investors. Key investors include BB Biotech, Immedica, MQS Management, and Venrock.
The ticker symbol of Neurocrine is NBIX on NASDAQ.